United States set
Menu Shopping cart $0 Search
Distributed product


  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Insulin-Like Growth Factor 2
  • Species:Human
Cat. No. Size Price

E30 96 wells (1 kit) $618,81
PubMed Product Details
Technical Data

Cat # changed from RMEE30 to E30


Sandwich ELISA, Biotin-labelled antibody


Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Range

0.02–3600 ng/ml

Limit of Detection

0.02 ng/ml


The kits are CE-IVD certified and intended for professional use.



  • European Union: for in vitro diagnostic use
  • Rest of the world: for research use only!
  • Measurement of IGF-II in non-extracted serum and plasma samples
  • Calibrated against the International Standard: WHO NIBSC 96/538
  • No interference by IGF-binding proteins through excess IGF-I
  • Precise measurement of very low IGF-II levels: high sensitivity of 0.02 ng/ml
  • Inter- and Intra-Assay variance: maximal 7.2 and 6.6%

Research topic

Growth hormone and factor-related products


The insulin-like growth factors (IGF)-1 and –2 play a pivotal role in the regulation of proliferation and differentiation
of several tissue types. IGF-1 also called Somatomedin C has a molecular weight of 7.469 kDa.
Its expression is mainly regulated by Growth Hormone and nutrition. But several hormones and peptide factors
are known to influence IGF-2 synthesis in different tissues. Bioavailability of the IGFs is regulated by specific
binding proteins (IGFBP). Beside the high affinity Insulin-like Growth Factor Binding Proteins 1-6, IGFs are also
bound be IGFBP-related Proteins. These binding proteins bind IGF-1 and IGF-2 with the same affinity or prefer IGF-2. Direct measurement of IGFs in serum samples without pretreatment results in false values because of the extremely slow dissociation of the IGF/IGFBP complexes during the assay incubation only a part of the IGF-2 in the specimen can bind to the antibodies and be detected.
Therefore, various techniques were applied to physically separate IGF-2 from its binding proteins before measurement, including (a) size exclusion chromatography under acidic conditions, (b) solid-phase extraction and (c) acid-ethanol extraction. These techniques, however, are either inconvenient or time-consuming or give incomplete and not-reproducible recoveries.
This assay is easy, fast and results do not depend on the binding protein concentration of the sample. Its based on the high specificity of the employed antibodies for IGF-2. There is virtually no cross-reactivity with IGF-1. This allows the separation of IGF-2 from the binding proteins by acidification and blocking of the free binding proteins with IGF-1. Thus, the endogenous IGF-2 is free in solution.

Product References (2)


  • Andreu-Fernández V, Bastons-Compta A, Navarro-Tapia E, Sailer S, Garcia-Algar O. Serum concentrations of IGF-I/IGF-II as biomarkers of alcohol damage during foetal development and diagnostic markers of Foetal Alcohol Syndrome. Sci Rep. 2019 Feb 7;9(1):1562. doi: 10.1038/s41598-018-38041-0. PubMed PMID: 30733584. PubMed CentralPMCID: PMC6367511. See more on PubMed
  • Disler PB, Jacka E, Sayed AR, Rip MR, Hurford S, Collis P. The prevalence of locomotor disability and handicap in the Cape Peninsula. Part II. The black population of Nyanga. S Afr Med J. 1986 Mar 15;69(6):353-5. PubMed PMID: 2938279. See more on PubMed
Related Products Docs